SLC5A2 and type 2 diabetes mellitus: A meta-analysis that included five SGLT2 inhibitor trials – three CV outcome trials of T2DM cohorts and two with participants living with HF – suggested that participants of Asian descent reaped greater CV death reduction/HF hospitalisation benefits relative to the White European individuals [27].